Hussain T, Lokhandwala M F
Institute for Cardiovascular Studies, College of Pharmacy, University of Houston, Texas 77204-5511, USA.
Hypertension. 1998 Aug;32(2):187-97. doi: 10.1161/01.hyp.32.2.187.
Dopamine plays an important role in the regulation of renal sodium excretion. The synthesis of dopamine and the presence of dopamine receptor subtypes (D1A, D1B, as D1-like and D2, and D3 as D2-like) have been shown within the kidney. The activation of D1-like receptors located on the proximal tubules causes inhibition of tubular sodium reabsorption by inhibiting Na,H-exchanger and Na,K-ATPase activity. The D1-like receptors are linked to the multiple cellular signaling systems (namely, adenylyl cyclase, phospholipase C, and phospholipase A2) in the different regions of the nephron. Defective renal dopamine production and/or dopamine receptor function have been reported in human primary hypertension as well as in genetic models of animal hypertension. There may be a primary defect in D1-like receptors and an altered signaling system in the proximal tubules that lead to reduced dopamine-mediated effects on renal sodium excretion in hypertension. Recently, it has been shown in animal models that the disruption of either D1A or D3 receptors at the gene level causes hypertension in mice. Dopamine and dopamine receptor agonists also provide therapeutic potential in treatment of various cardiovascular pathological conditions, including hypertension. However, because of the poor bioavailability of the currently available compounds, the use of D1-like agonists is limited to the management of patients with severe hypertension when a rapid reduction of blood pressure is clinically indicated and in acute management of patients with heart failure. In conclusion, there is convincing evidence that dopamine and dopamine receptors play an important role in regulation of renal function, suggesting that a defective dopamine receptor/signaling system may contribute to the development and maintenance of hypertension. Further studies need to be directed toward establishing a direct correlation between defective dopamine receptor gene in the kidney and development of hypertension. Subsequently, it may be possible to use a therapeutic approach to correct the defect in dopamine receptor gene causing the hypertension.
多巴胺在肾钠排泄的调节中起重要作用。已证实肾脏内存在多巴胺的合成以及多巴胺受体亚型(D1A、D1B 属于 D1 样受体,D2 和 D3 属于 D2 样受体)。位于近端小管的 D1 样受体被激活后,通过抑制钠氢交换体和钠钾 ATP 酶的活性,抑制肾小管钠重吸收。D1 样受体与肾单位不同区域的多种细胞信号系统(即腺苷酸环化酶、磷脂酶 C 和磷脂酶 A2)相关联。在人类原发性高血压以及动物高血压的遗传模型中,均报道了肾脏多巴胺生成和/或多巴胺受体功能存在缺陷。高血压患者近端小管中 D1 样受体可能存在原发性缺陷,信号系统也发生改变,从而导致多巴胺介导的肾钠排泄作用减弱。最近,在动物模型中发现,基因水平上 D1A 或 D3 受体的破坏会导致小鼠患高血压。多巴胺和多巴胺受体激动剂在治疗包括高血压在内的各种心血管病理状况方面也具有治疗潜力。然而,由于现有化合物的生物利用度较差,D1 样激动剂仅在临床表明需要快速降低血压时用于重度高血压患者的治疗,以及心力衰竭患者的急性处理。总之,有令人信服的证据表明多巴胺和多巴胺受体在肾功能调节中起重要作用,提示多巴胺受体/信号系统缺陷可能导致高血压的发生和维持。需要进一步开展研究,以确定肾脏中多巴胺受体基因缺陷与高血压发生之间的直接关联。随后,或许有可能采用治疗方法纠正导致高血压的多巴胺受体基因缺陷。